Rachel Vatnsdal
Stock Analyst at JP Morgan
(4.42)
# 337
Out of 4,748 analysts
52
Total ratings
65.79%
Success rate
14.94%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| A Agilent Technologies | Maintains: Overweight | $165 → $160 | $147.09 | +8.78% | 6 | Nov 26, 2024 | |
| WAT Waters | Maintains: Neutral | $340 → $380 | $404.17 | -5.98% | 3 | Nov 4, 2024 | |
| TXG 10x Genomics | Maintains: Neutral | $20 → $14 | $14.84 | -5.66% | 2 | Oct 30, 2024 | |
| TMO Thermo Fisher | Maintains: Overweight | $650 → $670 | $568.23 | +17.91% | 8 | Sep 20, 2024 | |
| HSIC Henry Schein | Maintains: Overweight | $88 → $80 | $79.87 | +0.16% | 3 | Aug 12, 2024 | |
| NVST Envista Holdings | Downgrades: Neutral | $23 → $16 | $21.37 | -25.13% | 3 | Aug 8, 2024 | |
| TEM Tempus AI | Maintains: Overweight | $42 → $47 | $50.77 | -7.43% | 2 | Aug 7, 2024 | |
| MYGN Myriad Genetics | Maintains: Underweight | $17 → $20 | $12.54 | +59.49% | 3 | Aug 7, 2024 | |
| AKYA Akoya Biosciences | Downgrades: Neutral | n/a | $3.00 | - | 2 | Aug 6, 2024 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,300 → $1,400 | $1,335.50 | +4.83% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $6 | $7.71 | -22.18% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $190 → $200 | $169.40 | +18.06% | 4 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $120 | $123.52 | -2.85% | 3 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.56 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $54.17 | +66.14% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $223.73 | +20.68% | 4 | Dec 20, 2023 |
Agilent Technologies
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $147.09
Upside: +8.78%
Waters
Nov 4, 2024
Maintains: Neutral
Price Target: $340 → $380
Current: $404.17
Upside: -5.98%
10x Genomics
Oct 30, 2024
Maintains: Neutral
Price Target: $20 → $14
Current: $14.84
Upside: -5.66%
Thermo Fisher
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $568.23
Upside: +17.91%
Henry Schein
Aug 12, 2024
Maintains: Overweight
Price Target: $88 → $80
Current: $79.87
Upside: +0.16%
Envista Holdings
Aug 8, 2024
Downgrades: Neutral
Price Target: $23 → $16
Current: $21.37
Upside: -25.13%
Tempus AI
Aug 7, 2024
Maintains: Overweight
Price Target: $42 → $47
Current: $50.77
Upside: -7.43%
Myriad Genetics
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $12.54
Upside: +59.49%
Akoya Biosciences
Aug 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.00
Upside: -
Mettler-Toledo International
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,335.50
Upside: +4.83%
Aug 2, 2024
Maintains: Overweight
Price Target: $5 → $6
Current: $7.71
Upside: -22.18%
Jul 31, 2024
Maintains: Overweight
Price Target: $190 → $200
Current: $169.40
Upside: +18.06%
Jul 30, 2024
Maintains: Neutral
Price Target: $105 → $120
Current: $123.52
Upside: -2.85%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.56
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $54.17
Upside: +66.14%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $223.73
Upside: +20.68%